Psychiatry · Medical Literature
[Comment] The direct and indirect effects of antipsychotic drugs on negative symptoms
Abstract
Antipsychotic drugs are often thought to have minimal effects on negative symptoms of schizophrenia spectrum disorders. In 1985, Tim Crow conceptualised one of the first biologically informed symptom dichotomies, characterising negative symptoms as poorly responsive to treatment.1 He warned that positive and negative syndromes might be independent yet co-existing, following a dynamic time-course within individuals.
Clinical relevance
Do antipsychotic drugs exert clinically meaningful direct and/or indirect effects on the negative symptoms of schizophrenia spectrum disorders, and how should this nuanced relationship inform clinical thinking? __SNAPSHOT__ {"studyDesign":"Expert commentary / opinion piece (not an original research study or systematic review); no primary data collection performed","setting":"Not applicable — published in The Lancet Psychiatry; authors are affiliated with academic psychiatric institutions in the Netherlands (University Medical Centre Groningen)","sampleSize":"Not applicable — no patient-level or aggregate study data reported","population":"Patients with schizophrenia spectrum disorders experiencing negative symptoms; no specific inclusion or exclusion criteria applicable given the commentary format","intervention":"Antipsychotic drug treatment (class-level discussion; specific agents not uniformly delineated in the abstract)","comparator":"Not applicable — no formal comparator group; conceptual contrast between direct antipsychotic effects on primary negative symptoms versus indirect effects mediated through positive symptom reduction or reduction of medication side effects","primaryOutcome":"Conceptual synthesis of whether antipsychotics have direct (acting on primary negative symptoms) versus indirect (mediated via positive symptom reduction, EPS reduction, or depressive symptom improvement) effects on negative symptom burden; no quantitative primary endpoint defined","followUp":"Not applicable","fundingSource":"Not reported"}
Key findings
This commentary revisits the longstanding clinical assumption — rooted in Tim Crow's 1985 two-syndrome model — that negative symptoms of schizophrenia spectrum disorders are poorly responsive to antipsychotic treatment. The authors distinguish between: (1) direct effects, referring to antipsychotic actions that reduce primary negative symptoms intrinsic to the illness itself; and (2) indirect effects, by which antipsychotics may improve negative symptoms secondarily through reduction of positive symptoms (e.g., reducing aversion-driven social withdrawal), amelioration of depressive symptoms, or mitigation of extrapyramidal side effects that can phenocopy negative symptoms. No original quantitative data, effect sizes, confidence intervals, p-values, or NNT/NNH values are reported in the abstract. The commentary does not itself establish whether either direct or indirect effects are clinically dominant. Contextual literature supports that secondary negative symptoms — attributable to positive symptoms, depression, social deprivation, or medication-induced side effects — are common, modifiable, and clinically important, whereas primary (deficit) negative symptoms remain substantially more refractory. The choice of antipsychotic agent (e.g., partial D2 agonists vs. high-affinity D2 antagonists) may differentially influence secondary negative symptom burden, as suggested by related work from the same research group.
Practice implications
This commentary challenges the clinical heuristic that antipsychotics are uniformly ineffective for negative symptoms, calling instead for a mechanistically nuanced framework distinguishing direct from indirect treatment effects. What the piece establishes (conceptually): that observed improvements in negative symptoms during antipsychotic treatment may reflect either true direct pharmacological action on primary pathology, or indirect benefits from suppressing positive symptoms, treating co-occurring depression, or reducing medication-induced parkinsonism/akinesia. What it does not establish: the relative magnitude or clinical importance of direct versus indirect contributions; whether any specific antipsychotic is superior for primary negative symptoms; or whether this framework should alter prescribing practices in the absence of supporting trial data. The patient population to whom this commentary most applies includes those with schizophrenia spectrum disorders across illness stages, but particularly those in whom secondary negative symptoms (from positive symptoms, EPS, or depression) may be driving observed negative symptom burden. Patients with established deficit syndrome (true primary negative symptoms stable over time, unconfounded by other psychopathology) are a critically underrepresented and more treatment-refractory group. IMPORTANT LIMITATION: Only the abstract was available for review. The full commentary may contain additional argumentation, supporting data synthesis, or clinical recommendations not captured here. This summary should be interpreted accordingly. __LIMITATIONS__ 1. Publication type: This is an expert commentary, not a systematic review, meta-analysis, or original trial — it represents expert opinion and conceptual synthesis, not new empirical evidence. 2. Abstract-only access: The full text was unavailable; key arguments, supporting evidence citations, and nuances of the authors' position may not be fully represented here. 3. No quantitative data: No effect sizes, confidence intervals, or p-values are reported; claims cannot be independently assessed for statistical or clinical magnitude. 4. Potential for author bias: The corresponding authors have a substantial body of work on antipsychotic D2 receptor affinity and negative symptoms in first-episode psychosis, which may shape framing. 4. Generalizability: Commentary-level arguments may not account for heterogeneity across illness stages, antipsychotic classes, symptom subtypes, or patient demographics. 5. Crow's 1985 framework is invoked as a historical anchor but has itself been substantially revised and contested in subsequent decades; the commentary's engagement with more recent negative symptom models (e.g., NIMH-MATRICS criteria, avolition-expressivity distinction) cannot be assessed from the abstract alone. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This Lancet Psychiatry commentary by Gangadin, de Beer, and Sommer challenges the entrenched view that antipsychotics are ineffective for negative symptoms, proposing a mechanistic distinction between direct effects on primary negative symptoms and indirect effects mediated through positive symptom, depression, and EPS reduction. As an expert opinion piece without original data, it does not change prescribing practice on its own, but it provides a clinically useful framework for individualizing assessment and management of negative symptoms — particularly in identifying and targeting modifiable, secondary contributors. Clinicians should routinely attempt to disentangle primary from secondary negative symptoms, as the latter may respond meaningfully to antipsychotic optimization or adjunctive strategies.